The endless cycle of mergers is no answer to the basic growth problems of now oversized pharmaceutical companies, in part because little real restructuring goes on with the acquirer, who needs it as much as the target. But one set of acquirers we haven't heard from could accomplish a lot of the necessary reforms: the large IT companies who could apply not only their technologies to improve marketing and business practices in the drug industry, but their management philosophies.
You may also be interested in...
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.